Smith & Nephew SNATS – Consensus Indicates Potential 30.9% Upside

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Smith & Nephew SNATS with ticker code (SNN) now have 3 analysts in total covering the stock. The consensus rating is ‘Strong_Buy’. The target price ranges between 47 and 40 and has a mean target at 43.67. Now with the previous closing price of 33.36 this indicates there is a potential upside of 30.9%. The day 50 moving average is 33.8 and the 200 day moving average is 37.83. The company has a market capitalisation of $14,733m. You can visit the company’s website by visiting: https://www.smith-nephew.com

The potential market cap would be $19,287m based on the market concensus.

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    Smith & Nephew's Q3 2024 update shows a 4% revenue growth to $1,412M. Despite China headwinds, US Orthopaedics and Sports Medicine excelled.
    Smith & Nephew plc (LON:SN, NYSE:SNN) reports a robust financial performance for Q2 and H1 2024, showing significant revenue and profit growth.
    Smith+Nephew plc reports solid financial results for Q4 and full year 2023, showcasing growth in revenue and profit margins. Analyst call scheduled for 27 Feb 2024.
    Smith+Nephew plc (LON:SN, NYSE:SNN) will be attending AAOS 2024 Annual Meeting to showcase its innovative medical technology solutions in San Francisco. Learn about their latest products and updates in the orthopaedic field.

      Search

      Search